Loading...
TKT R438W
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. TKT R438W is characterized as subdominant antigens as T cell immunity required peptide vaccination and these neoantigens are processed and presented from endogenously expressed protein.
- Recombinant Human Anti-TKT R438W Soluble TCR (MEL21) (KIH) (VS-0622-YF7881)
-
- Epitope: AMFWSVPTV
- MHC: HLA-A*02:01
-
- Epitope: AMFWSVPTV
- MHC: HLA-A*02:01
- Human Anti-TKT R438W Recombinant Soluble TCR (clone MEL21) (scTCR-1176YC-S(P))
-
- Epitope: AMFWSVPTV
- MHC: HLA-A*02:01
- Recombinant Human Anti-TKT R438W Soluble TCR (MEL21) (C-Cys) (VS-0622-YF5173)
-
- Epitope: AMFWSVPTV
- MHC: HLA-A*02:01
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
For Research Use Only. Not For Clinical Use.